Core Viewpoint - The company held a performance briefing to provide insights into its 2024 annual report and Q1 2025 results, addressing investor concerns and outlining strategies for navigating industry challenges and opportunities [1][2]. Performance Briefing Overview - The performance briefing was conducted on June 30, 2025, with key executives present to engage with investors and respond to their inquiries [2]. Industry Trends and Company Strategy - The retail pharmacy industry is undergoing significant transformation, with a closure rate of approximately 5.7% in 2024, leading to an accelerated industry consolidation [2][3]. - The company aims to leverage this consolidation by enhancing compliance, improving service quality, and expanding its market share through franchise and alliance models [2][3]. Profitability and Cost Management - The company is focused on cost reduction and efficiency improvements, targeting over 100 million yuan in cost savings for 2025 through various initiatives [3][4]. - A comprehensive reform of the procurement system is underway to enhance supply chain efficiency and align product offerings with consumer needs [4]. Expansion Plans - The company plans to open 1,000 new stores in 2025, primarily through franchise models, while also converting existing stores to franchises [5]. - The strategy includes focusing on existing markets to increase market share and profitability [5]. Diversification Opportunities - The company is pursuing service diversification, including chronic disease management and community health services, to enhance customer engagement and loyalty [6]. - Product diversification efforts are focused on expanding non-pharmaceutical categories, with a reported 9% year-over-year increase in sales of general food and personal care products in Q1 2025 [6]. Market Positioning and Competitive Advantage - The company emphasizes its competitive advantages in offline retail, including immediate service, professional advice, and health management services, particularly in lower-tier cities [7][8]. - The company has established a robust compliance framework to navigate regulatory challenges and maintain its market position [12]. ESG Initiatives - The company has integrated ESG principles into its operations, achieving a rating upgrade from BBB to A in the WindESG assessment for 2024 [10][11]. Financial Returns and Shareholder Engagement - The company has committed to distributing at least 50% of its net profit as cash dividends from 2024 to 2026, reflecting a strong commitment to shareholder returns [13][17]. - Cumulative cash dividends since its IPO amount to 2.069 billion yuan, demonstrating a consistent return to investors [17]. Franchise and Alliance Business Development - As of Q1 2025, the company has established 5,408 franchise stores and over 21,000 alliance stores, with significant growth in alliance business sales [14].

证券代码：603883 证券简称：老百姓 公告编号：2025-033 老百姓大药房连锁股份有限公司关于 2024 年度暨 2025 年 第一季度业绩说明会召开情况的公告（2025 年 6 月纪要） 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 4 月 30 日 在上海证券交易所网站（http://www.sse.com.cn）及指定信息披露媒体披露了 《老百姓大药房连锁股份有限公司 2024 年年度报告》《老百姓大药房连锁股份有 限公司 2025 年一季度报告》。为使广大投资者更加全面、深入地了解公司情况， 公司于 2025 年 6 月 30 日召开了 2024 年度暨 2025 年第一季度业绩说明会，现将 会议召开情况公告如下： 一、业绩说明会召开基本情况 2025 年 6 月 21 日，公司在上海证券交易所网站（http://www.sse.com.cn） 及指定信息披露媒体披露了《关于召开 2024 年度暨 2025 年第一季度业绩说明会 的公告》。 ...

Core Viewpoint - The company aims to enhance its sustainable competitive advantage through comprehensive value chain reforms, despite facing challenges in revenue and profit due to new store openings and goodwill impairment losses [1]. Group 1: Financial Performance - In 2024, the company achieved a revenue of 22.358 billion yuan, a slight decrease of 0.36% year-on-year, while the net profit attributable to shareholders was 519 million yuan, down 44.13% [1]. - The decline in net profit is attributed to the increase in the number of new stores, which are still in the performance growth phase, and the company's recognition of goodwill impairment losses [1]. Group 2: Industry Trends and Strategy - The pharmaceutical retail industry is undergoing significant transformation, shifting from rapid expansion to a phase of differentiation and consolidation [1]. - In the first quarter of 2025, the company reported a net decrease in stores, with 211 new stores opened and 236 closed, resulting in a total reduction of 25 stores [1]. - The company plans to open 1,000 stores in 2025, primarily focusing on franchise stores and converting existing stores to franchises, while also pursuing strategic acquisitions in advantageous markets [1]. Group 3: Compliance and Ecosystem Development - The company emphasizes strengthening its compliance system and self-inspection mechanisms to ensure compliant operations, aiming to enhance store operational quality [2]. - The focus is on developing franchise and alliance businesses to integrate industry resources and build an ecosystem with small and medium-sized pharmacies, aiming to capture opportunities during the industry consolidation phase and increase market share [2]. Group 4: R&D and AI Initiatives - The company has been recognized as a technology center since 2011 and allocates approximately 0.6% of its total revenue annually for R&D, focusing on product and technology development [3]. - The company has developed over 70 self-researched business system products and obtained 102 software copyrights, supporting efficient business operations [3]. - An AI application strategy committee has been established to ensure the implementation of AI initiatives across various business areas, including the development of multiple generative dialogue assistants for different scenarios [3]. Group 5: Future Outlook - The company envisions a transformation from a single "pharmaceutical sales terminal" to a "comprehensive health service complex," aiming to meet evolving consumer health demands [3]. - The strategy includes deepening professional pharmaceutical services, enhancing prescription outsourcing capabilities, and expanding diverse service scenarios through physical pharmacies to create a health community ecosystem [3].

Core Viewpoint - The retail pharmacy industry is experiencing accelerated closures, with a total of 39,228 stores shut down in 2024, leading to a potential recovery in customer traffic and profit margins for leading pharmacies post-industry consolidation [1][2]. Group 1: Industry Trends - The number of closed pharmacies in 2024 is reported as follows: Q1 - 6,778, Q2 - 8,791, Q3 - 9,545, Q4 - 11,414, indicating a significant acceleration in closures, with a net decrease of 3,395 stores in Q4 alone [1]. - The industry is facing a severe environment for small and medium-sized pharmacies due to weak consumer power, medical insurance cost control, and enhanced regulatory measures, leading to a consolidation trend [1]. Group 2: Market Opportunities - Leading retail pharmacies are expected to benefit from a "siphon effect" in customer traffic due to their first-mover advantage in local market outpatient coordination, which may enhance customer spending and overall performance [2]. - The implementation of outpatient coordination policies is anticipated to increase medical insurance spending and related product consumption, potentially raising average transaction values [2]. Group 3: Strategic Initiatives - Leading pharmacies are actively exploring diversified operations and innovative store management to enhance market competitiveness, such as transforming into service complexes and creating new store formats [3]. - Examples include Yifeng Pharmacy's transition towards service complexes and Yixin Hall's development of new store formats to attract more customers [3]. Group 4: Recommended Stocks - Companies that are expected to benefit from the industry cycle and demonstrate superior management capabilities include Yifeng Pharmacy (603939.SH) and Daclin (603233.SH) as recommended stocks, while beneficiaries include Laobaixing (603883.SH), Yixin Hall (002727.SZ), and Jianzhijia (605266.SH) [4].

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Viewpoints - The industry is experiencing accelerated consolidation, with leading retail pharmacies expected to rebound first. The number of closed pharmacies in 2024 reached a total of 39,228, indicating a significant industry cleanup. This is expected to enhance customer traffic and profit margins for leading pharmacies [4][5] - The implementation of outpatient coordination is anticipated to bring performance growth, as leading retail pharmacies can attract more customers and increase average transaction values through enhanced insurance coverage and related product consumption [5] - Leading retail pharmacies are actively exploring diversified operations to enhance market competitiveness, with innovative store formats and service models being developed to attract more customers [6] Summary by Sections Industry Overview - The closing price of the industry is 4975.11, with a 52-week high of 5679.6 and a low of 4139.32 [1] Industry Performance - The relative performance of the pharmaceutical commercial sector shows a gradual improvement, with a 21% increase noted by June 2025 compared to earlier months [3] Recommendations and Beneficiaries - Recommended stocks include Yifeng Pharmacy and Daclin, while beneficiaries include Laobaixing, Yixintang, and Jianzhijia [7]

Group 1 - The report highlights a resilient actual GDP growth forecast of over 5% for Q2 2025, despite nominal GDP pressures due to declining economic data, particularly in real estate investment [6][7] - The report emphasizes the importance of domestic demand and technology as key investment themes, especially in light of the upcoming political bureau meeting that will outline economic policies for the second half of the year [7][8] - The agricultural sector, particularly pig farming, is expected to see a price increase due to reduced supply pressure and improved profitability, with specific companies like Muyuan Foods and Wens Foodstuffs recommended for investment [8][9][10] Group 2 - The pharmaceutical and biotechnology sector is gradually stabilizing, with a reported revenue of CNY 795.03 billion in the first four months of 2025, a year-on-year decline of 2.1% [12][13] - The report notes a significant increase in the number of innovative drug projects and collaborations, with 51 innovative drug projects worth over USD 48 billion completed in the first five months of 2025 [13][14] - Investment recommendations include focusing on innovative drug companies with differentiated products and strong potential for international expansion, such as Kelun Pharmaceutical and Betta Pharmaceuticals [14][27] Group 3 - The basic chemical sector is experiencing a recovery, with the SW basic chemical index outperforming the market, driven by a decrease in raw material costs and potential supply-side reforms [16][17] - Companies with strong cost advantages and those involved in supply-side reforms, such as Hoshine Silicon Industry and Zhejiang Longsheng, are highlighted as potential investment opportunities [18][19] - The report also points to new consumer trends driving demand for health additives and domestic substitutes in the chemical materials sector, with companies like Jinfa Technology and Shengquan Group recommended for investment [19] Group 4 - The electronics sector is witnessing a recovery, with Xiaomi's launch of its first AI glasses and other innovative products expected to strengthen its market position [20][21] - The report indicates a 4.61% increase in the electronic index, outperforming the broader market, with specific focus on AI-driven sectors and semiconductor equipment as key investment areas [22][23] - Recommended companies include companies benefiting from strong domestic and international demand in the AIOT field, such as Espressif Systems and Rockchip Electronics [23] Group 5 - The GLP-1 drug market is gaining attention with the approval of the first dual-target weight loss drug in China, which is expected to drive further interest in the sector [24][26] - The report notes that the pharmaceutical sector's overall performance has been mixed, with a 1.60% increase in the biopharmaceutical index, but specific segments like medical services and devices are performing well [25][27] - Investment suggestions include focusing on companies involved in innovative drug development and medical devices, such as Betta Pharmaceuticals and Yao Ming Pharmaceutical [27][28]

Meeting Details - The shareholders' meeting was held on June 30, 2025, at the company's conference room in Changsha, Hunan Province [1] - The meeting was attended by shareholders representing 50.8455% of the total shares [1] - Voting was conducted through a combination of on-site and online methods, and the meeting was presided over by Chairman Xie Zilong [1] Voting Results - All non-cumulative voting proposals were approved with high support, including: - Proposal 1: 99.9280% approval from A-shareholders [1] - Proposal 2: 99.9237% approval from A-shareholders [1] - Proposal 3: 99.9208% approval from A-shareholders [1] - Proposal 4: 99.9272% approval from A-shareholders [1] - The voting results indicate a strong consensus among shareholders for the proposed resolutions [2][3] Legal Compliance - The meeting's procedures were confirmed to comply with the Company Law and relevant regulations, ensuring the legality and validity of the meeting and voting results [4]

证券代码：603883 证券简称：老百姓 公告编号：2025-031 老百姓大药房连锁股份有限公司 关于控股股东股票解押及再质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●老百姓大药房连锁股份有限公司（以下简称"公司"）控股股东老百姓医药集 团有限公司（以下简称"医药集团"）持有公司股份数量为 191,729,175 股，占公司 总股本比例为 25.22%；累计质押股份数量为 118,950,000 股（含本次质押），占其所 持股份比例为 62.04%，占公司总股本比例为 15.65%。控股股东及一致行动人（医药集 团与陈秀兰）合计持有公司股份数量为 205,294,873 股，占公司总股本比例为 27.01%； 累计质押股份数量为 118,950,000 股（含本次质押），占其所持股份比例为 57.94%， 占公司总股本比例为 15.65%。 一、控股股东本次股份质押解除具体情况 公司于 2025 年 6 月 27 日获悉控股股东医药集团在中国证券登记结算有限责任公 司上海分公司办理了将质押给 ...

为出具本法律意见书，本所声明如下： 湖南启元律师事务所 关于老百姓大药房连锁股份有限公司 2024年年度股东大会的 法律意见书 二零二五年六月三十日 致：老百姓大药房连锁股份有限公司 湖南启元律师事务所（以下简称"本所"）接受老百姓大药房连锁股份有限 公司（以下简称"公司"）的委托，指派律师出席了公司 2024 年年度股东大会（以 下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员 及召集人的资格、表决程序和表决结果的合法有效性进行律师见证，并发表本法 律意见。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《老百姓 大药房连锁股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具 本法律意见书。 （一）本所出具本法律意见书是基于公司已承诺所有提供给本所的文件的正 本以及经本所查验与正本保持一致的副本均为真实、完整、可靠，无隐瞒、虚假 或重大遗漏之处。 （二）本所遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对本法 律意见书 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-032 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 30 日 (二)股东大会召开的地点：湖南省长沙市开福区青竹湖路 808 号老百姓 15 楼会 议室 老百姓大药房连锁股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 342 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 386,474,468 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 50.8455 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票和网络投票相结合的方式召开，老百姓大药房连锁股份有 限公司（以下简称"公司"）董事会召集本次会议，本次 ...